Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Example input: "Although the story didn't cite the cost of appendectomy emergency or urgent surgery and we wish it had, we nonetheless will give it a satisfactory score because it at least cited what the editorial writer wrote, ""A secondary benefit is the savings to the hospital generated by minimizing staff and anesthesiologist presence late in the evening and during the wee hours of the morning."" As with our harms score above, although the story didn't give absolute numbers, in this case we think it was sufficient for it to report that ""The scientists found no significant difference among the groups in the patients' condition 30 days after surgery or in the length of their operation or hospital stay."" Although the story didn't give absolute numbers, in this case we think it was sufficient for it to report that ""The scientists found no significant difference among the groups in the patients' condition 30 days after surgery or in the length of their operation or hospital stay."" Despite running less than 300 words, this story did an adequate job in explaining the quality of the evidence, including pointing out limitations. No disease-mongering here. The story meets the bare minimum requirement for this criterion in that it at least cited what an editorial stated. The focus of the story was on a study comparing emergency appendectomy with surgery done up to 12 hours later or beyond. This is the whole focus of the story and one we applaud when it begins: ""Appendectomy is the most common emergency surgery in the world, but it doesn't have to be."" There were no claims made about the novelty of this research, and we may have wished for a bit more context on this. Nonetheless, the potential for guiding future care decisions was made clear. Not applicable. Given that the story only pulled excerpts from the journal article and the accompanying editorial, and didn't include any fresh quotes from interviews, we can't be sure of the extent to which it may have been influenced by a news release."
Example output: Some appendicitis cases may not require 'emergency' surgery
Example explanation: The paragraph mentions that "Appendectomy is the most common emergency surgery in the world, but it doesn't have to be." which is considered evidence for the output. Thus, the output is a valid claim.
Q: The recall brings into question the safety of European supplies of the drug, which become the target of a U.S. investigation after a spike in fatalities and severe reactions in some patients taking heparin sold by Baxter International Inc. "What is significant about the German recall is that the heparin active ingredient in their product was not obtained from SPL," or Scientific Protein Labs, Baxter's supplier, FDA Deputy Commissioner Janet Woodcock said. "We're concerned about worldwide, this contaminant, in heparin and making sure it is safe, (and) out of the heparin supply," Woodcock said. German authorities do not expect a shortage of the drug, FDA said. The FDA began probing Baxter's heparin several weeks ago after it was linked with to four deaths and hundreds of severe reactions, such as breathing problems and rapid drops in blood pressure. On Wednesday it said it identified a contaminant that may be linked with the drug's problems. Some 19 fatalities have now been associated with use of the drug in the United States, the FDA said on Wednesday. However, all the deaths have not been linked to a specific drug maker. The other major U.S. heparin supplier, APP Pharmaceuticals Inc, has ramped up production to avoid a drug shortage. Tests on APP's heparin have not found any contamination, Woodcock said on Wednesday. No fatalities were seen in Germany, and "less than 100" severe reactions led to the recall, the FDA said. The German product manufacturer, Rotexmedica GmbH, could not be immediately reached for comment. Heparin is derived from pig intestines. It is used in dialysis and heart procedures, among other surgeries, to avoid blood clots. FDA officials also advised companies and countries to begin using a sophisticated testing technique the agency used to find the potential contaminant, to test all heparin on the market. "With this testing method, there will be a way to protect the heparin supply," Woodcock said. Baxter's main supplier is Wisconsin-based Scientific Protein Laboratories LLC (SPL), which has a major facility in China, a main subject of FDA's investigation. About 80 percent of the active pharmaceutical ingredients come from foreign sources, according to U.S. government investigators. Most of the world's heparin supply is from China, according to Baxter. The FDA inspects only about 7 percent of foreign manufacturing facilities annually, according to the Government Accountability Office, a congressional watchdog agency. China's reputation has been tainted after health scares with pigs and massive recalls of pet food and children's toys containing lead paint. Sidney Wolfe, head of health research at the consumer group Public Citizen, said the FDA has poorly allocated its resources for inspections. "China has a tiny fraction of plants being inspected as opposed to India, which is dangerous considering that China is a country far less advanced," Wolfe said. The FDA conducted about 13 inspections at Chinese plants in 2007, versus 65 at plants in India. China has 714 facilities against India's 410, according to the GAO report. Baxter has recalled most of its U.S. supplies of the drug. It sells the product in other European countries but not in Germany. But Baxter does not sell the specific vial-based product linked to the four U.S. deaths in European markets, company spokeswoman Erin Gardiner said.
A:
FDA says Germany recalls blood-thinner heparin.